New review shows statins remain first-line therapy in MASLD, while PCSK9 inhibitors offer potential but require more evidence. Learn more about evolving treatment guidance.

At the Liver Meeting sponsored by the American Association for the Study of Liver Diseases, investigators presented new insights into how the immune makeup of fibrotic tissue may influence ...

We read with great interest the article of Ratziu and colleagues, who evaluated the potential of thrombospondin-2 (TSP2), insulin-like growth factor binding protein 7, CD163 and growth differentiation ...

Panelists discuss how next-generation metabolic and hepatic agents are broadening treatment options and reshaping the MASH ...